Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis

Genetics in Medicine

Volumn 12, Issue 10, 2010, Pages 606-615

  Dahabreh, Issa J ^a   Kitsios, Georgios D ^a   Kent, David M ^a   Trikalinos, Thomas A ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

metaanalysis; paraoxonase 1; PON1; rs662; rs854560; stroke

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ALLELE; ARTICLE; BRAIN ISCHEMIA; CORONARY RISK; DOMINANT INHERITANCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; RECESSIVE INHERITANCE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ALLELES; ARYLDIALKYLPHOSPHATASE; BRAIN ISCHEMIA; CONFIDENCE INTERVALS; CORONARY DISEASE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; STROKE;

EID: 78049272263     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181ee81c6     Document Type: Article

References (47)

1. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-154.
2. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004;37:1317-1323.
3. Roest M, Jansen AC, Barendrecht A, Leus FR, Kastelein JJ, Voorbij HA. Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. Clin Biochem 2005;38:123-127.
4. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxo-nase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-695.
5. Lawlor DA, Day IN, Gaunt TR, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 2004;5:17.
6. Humphries SE, Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004;3:227-235.
7. Morrison AC, Bare LA, Luke MM, et al. Single nucleotide polymorphisms associated with coronary heart disease predict incident ischemic stroke in the atherosclerosis risk in communities study. Cerebrovasc Dis 2008;26:420-424.
8. Luke MM, Lalouschek W, Rowland CM, et al. Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: Vienna stroke registry. Cerebrovasc Dis 2009;28:499-504.
9. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 2006;163:300-309.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
11. Cochran W. The combination of estimates from different experiments. Biometrics 1954;10:101-129.
12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
13. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
14. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25: 3443-3457.
15. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005;58:894-901.
16. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-309.
17. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med 2003;22:2693-2710.
18. Salanti G, Higgins JP, Trikalinos TA, Ioannidis JP. Bayesian meta-analysis and meta-regression for gene-disease associations and deviations from Har-dy-Weinberg equilibrium. Stat Med 2007;26:553-567.
19. Thomas DC, Clayton DG. Betting odds and genetic associations. J Natl Cancer Inst 2004;96:421-423.
20. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442.
21. Ioannidis JP, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 2006;164:609-614.
22. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80.
23. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxo-nase 192 Gln-S>Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002;33:1459-1464.
24. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004;61:351-356.
25. Aydin M, Gencer M, Cetinkaya Y, et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life 2006; 58:165-172.
26. Baum L, Ng HK, Woo KS, et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006;39:191-195.
27. Can Demirdogen B, Turkanoglu A, Bek S, et al. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008;41:1-9.
28. Huang Q, Liu YH, Yang QD, et al. Human serum paraoxonase gene polymorphisms, Q192R andL55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurol Res 2006;28:549-554.
29. Imai Y, Morita H, Kurihara H, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435-442.
30. Lansbury AJ, Catto AJ, Carter AM, Bamford JM, Grant PJ. The paraoxonase glutamine/arginine polymorphism and cerebrovascular disease. Cerebrovasc Dis 2004;7:353-355.
31. Pasdar A, Ross-Adams H, Cumming A, et al. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 2006;7:28.
32. Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the para-oxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005;36:2346-2350.
33. Schiavon R, Turazzini M, De Fanti E, et al. PON1 activity and genotype in patients with arterial ischemic stroke and in healthy individuals. Acta Neurol Scand 2007;116:26-30.
34. Shin BS, Oh SY, Kim YS, Kim KW. The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol Scand 2008;117:237-243.
35. Slowik A, Wloch D, Szermer P, et al. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis 2007;23:395-400.
36. Topic E, Simundic AM, Ttefanovic M, et al. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin Chem Lab Med 2001;39:346-350.
37. Ueno T, Shimazaki E, Matsumoto T, et al. Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. MedSci Monit 2003;9:CR208-CR212.
38. Wang X, Cheng S, Brophy VH, et al. A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke 2009;40:683-695.
39. Xu X, Li J, Sheng W, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 2008;26:48-62.
40. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000;20:2441-2447.
41. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001;68:1428-1436.
42. Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur JG. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol Biomarkers Prev 2005;14:731-734.
43. Thyagarajan B, Jacobs DR Jr, Carr JJ, et al. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2008;54:738-746.
44. Rainwater DL, Rutherford S, Dyer TD, et al. Determinants of variation in human serum paraoxonase activity. Heredity 2009;102:147-154.
45. Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P. Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS One 2010;5:e9136.
46. Carlson CS, Heagerty PJ, Hatsukami TS, et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J Lipid Res 2006;47:1014-1024.
47. Fan AZ, Yesupriya A, Chang MH, et al. Gene polymorphisms in association with emerging cardiovascular risk markers in adult women. BMC Med Genet 2010;11:6.